Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEHRAN MOUSSAVIAN

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1689788234
CMS profile
349364
Location
CHULA VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$16,172.80

123 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEHRAN MOUSSAVIAN

NPI 1689788234 · CMS profile ID 349364

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

CHULA VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689788234?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEHRAN MOUSSAVIAN, NPI 1689788234, CMS profile ID 349364. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689788234?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MEHRAN MOUSSAVIAN, NPI 1689788234, CMS profile ID 349364. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689788234?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MEHRAN MOUSSAVIAN, NPI 1689788234, CMS profile ID 349364, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1689788234?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

123 matching records · $16,172.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 123 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 123.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $1,000.0006/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885737349 CMS
Janssen Pharmaceuticals, Inc $23.8906/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885737375 CMS
Boston Scientific Corporation $10.6406/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916764183 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.3506/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 876380297 CMS
Medtronic, Inc. $13.0206/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933512409 CMS
Boston Scientific Corporation $22.6005/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916764195 CMS
ABIOMED $31.4505/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942050187 CMS
Novo Nordisk Inc $15.4405/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898929927 CMS
E.R. Squibb & Sons, L.L.C. $14.9005/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932729173 CMS
BIOTRONIK INC. $29.5705/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949022225 CMS
Amgen Inc. $12.9905/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939790031 CMS
Abbott Laboratories $1.7405/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914253197 CMS
Abbott Laboratories $117.4805/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914253209 CMS
Abbott Laboratories $162.8305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914253219 CMS
Abbott Laboratories $20.0005/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914253231 CMS
Abbott Laboratories $23.0205/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914253235 CMS
Impulse Dynamics (USA) Inc. $32.6005/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947553305 CMS
ABIOMED $35.9505/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942050167 CMS
Boston Scientific Corporation $11.0605/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916764185 CMS
Edwards Lifesciences Corporation $177.7905/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943853779 CMS
Cardiovascular Systems Inc. $8.0505/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947948527 CMS
Abbott Laboratories $12.4605/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920541851 CMS
Abbott Laboratories $16.8105/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920541857 CMS
Saranas, Inc. $32.5504/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906429571 CMS
Abbott Laboratories $14.8904/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920559209 CMS
Abbott Laboratories $20.2904/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920559215 CMS
Medtronic, Inc. $12.6404/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933512407 CMS
Impulse Dynamics (USA) Inc. $25.7104/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947553303 CMS
Janssen Pharmaceuticals, Inc $12.4304/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885737381 CMS
Janssen Pharmaceuticals, Inc $7.1204/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885737395 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $14.0904/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 876380299 CMS
Boston Scientific Corporation $21.6704/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916764193 CMS
Esperion Therapeutics, Inc. $14.0404/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947272597 CMS
CVRx, Inc. $21.3204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946241113 CMS
Astellas Pharma US Inc $23.6603/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940158291 CMS
Medtronic, Inc. $21.0103/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933512405 CMS
Amgen Inc. $24.0103/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939790027 CMS
E.R. Squibb & Sons, L.L.C. $17.9303/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932729159 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.4703/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 876380301 CMS
Actelion Pharmaceuticals US, Inc. $4.7803/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885371071 CMS
Abbott Laboratories $3.2503/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914253205 CMS
Abbott Laboratories $19.2703/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914253225 CMS
Canon Medical Systems USA, Inc. $22.6303/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905482023 CMS
Canon Medical Systems USA, Inc. $31.3403/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905482177 CMS
Abbott Laboratories $4.9203/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907939479 CMS
ABIOMED $55.8903/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942049847 CMS
AstraZeneca Pharmaceuticals LP $16.2803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915187559 CMS
Edwards Lifesciences Corporation $161.3803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943853723 CMS
AstraZeneca Pharmaceuticals LP $15.3403/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915883357 CMS
Canon Medical Systems USA, Inc. $169.0903/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905481979 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $57,538.56 231
PY2020 $10,361.83 185
PY2021 $29,318.44 214
PY2022 $16,172.80 123
PY2023 $5,370.48 98
PY2024 $18,903.96 52
PY2025 $10,932.81 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $362,340.00 24
PY2024 Principal investigator $639,464.62 25
PY2023 Principal investigator $161,375.37 14
PY2022 Principal investigator $207,507.84 13
PY2021 Principal investigator $32,594.20 21
PY2020 Principal investigator $2,974.50 13
PY2019 Principal investigator $4,485.00 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $16,573.00 12/12/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169228
Principal investigator 1 Boston Scientific Corporation $16,539.10 12/09/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571873
Principal investigator 1 Boston Scientific Corporation $19,103.80 11/25/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571871
Principal investigator 1 Janssen Research & Development, LLC $23,925.00 11/19/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169134
Principal investigator 1 Janssen Research & Development, LLC $23,333.00 11/07/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169167
Principal investigator 1 Janssen Research & Development, LLC $950.00 11/03/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169271
Principal investigator 1 Boston Scientific Corporation $10,803.60 10/28/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571869
Principal investigator 1 Janssen Research & Development, LLC $15,332.00 09/19/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168934
Principal investigator 1 Boston Scientific Corporation $3,050.80 09/16/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571867
Principal investigator 1 Boston Scientific Corporation $300.00 08/26/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571865
Principal investigator 1 Janssen Research & Development, LLC $22,119.00 08/25/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168926
Principal investigator 1 Janssen Research & Development, LLC $16,768.00 07/23/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168949
Principal investigator 1 Janssen Research & Development, LLC $4,506.00 06/23/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169159
Principal investigator 1 Janssen Research & Development, LLC $18,410.00 06/20/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169176
Principal investigator 1 Boston Scientific Corporation $650.00 05/27/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571863
Principal investigator 1 Janssen Research & Development, LLC $24,533.00 05/21/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168921
Principal investigator 1 Janssen Research & Development, LLC $22,501.00 04/23/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169119
Principal investigator 1 Boston Scientific Corporation $2,323.10 04/08/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571861
Principal investigator 1 Janssen Research & Development, LLC $17,383.00 03/21/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169061
Principal investigator 1 Boston Scientific Corporation $14,908.20 03/11/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571859
Principal investigator 1 Janssen Research & Development, LLC $29,783.00 02/19/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168913
Principal investigator 1 Boston Scientific Corporation $11,636.50 02/11/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571857
Principal investigator 1 Janssen Research & Development, LLC $40,006.00 01/22/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168982
Principal investigator 1 Boston Scientific Corporation $6,902.90 01/14/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571855